Fig. 2: Progression-free survival and overall survival according to compliance with recommendation of Molecular Tumor Board and matching scores. | Nature Communications

Fig. 2: Progression-free survival and overall survival according to compliance with recommendation of Molecular Tumor Board and matching scores.

From: Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Fig. 2

a Progression-free survival according to compliance with recommendation of the Molecular Tumor Board (N = 429). Progression-free survival was significantly longer when Molecular Tumor Board recommendations were followed in full (group A) when compared to patients who received physician choice regimen (group C) (A vs. C: HR, 0.68; 95% CI, 0.51–0.90; P = 0.008, A vs. B: HR, 0.80; 95% CI, 0.60–1.06; P = 0.122, B vs. C: HR, 0.85; 95% CI, 0.67–1.06; P = 0.153). b Overall survival according to compliance with recommendation of Molecular Tumor Board (N = 429). Overall survival was significantly longer when Molecular Tumor Board recommendations were followed in full (group A) when compared to patients treated with physician choice regimen (group C). (A vs. C: HR, 0.69; 95% CI, 0.49–0.98; P = 0.036, A vs. B: HR, 0.72; 95% CI, 0.51–1.01; P = 0.056, B vs. C: HR, 0.97; 95% CI, 0.74–1.27; P = 0.815). c Progression-free survival according to matching scores (N = 429). Progression-free survival was longer among higher Matching Score groups (groups A and B) when compared to lower Matching Score patients (Group D) (A vs. D: HR, 0.47; 95% CI, 0.32–0.69; P < 0.001, B vs. D: HR, 0.71; 95% CI, 0.54–0.94; P = 0.018). Similarly, Group A versus C differed significantly, with Group A doing better (A vs. C: HR, 0.53; 95% CI, 0.34–0.82; P = 0.004) and there was a trend for Group A to be better than Group B (A vs. B: HR, 0.66; 95% CI, 0.43–1.01; P = 0.057). There was no significant difference between Group B vs. C (B vs. C: HR, 0.81; 95% CI, 0.57–1.15; P = 0.23). d Overall survival according to the matching scores (N = 429). Overall survival was longer among higher Matching Score groups (Group A) when compared to lower Matching Score (Group D) and trended longer for Group B vs. D and for Group A vs. C (A vs. D: HR, 0.55; 95% CI, 0.34–0.87; P = 0.011, B vs. D: HR, 0.72; 95% CI, 0.51–1.03; P = 0.071, A vs. C: HR, 0.59; 95% CI, 0.35–1.01; P = 0.053). There was however no difference between survival in groups A vs. B and B vs. C (A vs. B: HR, 0.76; 95% CI, 0.44–1.30; P = 0.312. B vs. C: HR, 0.79; 95% CI, 0.51–1.21; P = 0.269).

Back to article page